-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Nabriva Therapeutics plc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2014 to 2022.
- Nabriva Therapeutics plc Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2023 was -$12.1M, a 8.92% decline year-over-year.
- Nabriva Therapeutics plc Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2023 was -$55.1M, a 18.1% decline year-over-year.
- Nabriva Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2022 was -$57.2M, a 15.6% decline from 2021.
- Nabriva Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2021 was -$49.5M, a 28.8% increase from 2020.
- Nabriva Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2020 was -$69.5M, a 16% increase from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)